GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T-cell death

Antiviral Therapy

Volumn 17, Issue 7, 2012, Pages 1271-1279

  Rydze, Robert T ^a,b,c   Bhattarai, Nirjal ^a,c   Stapletone, Jack T ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; INTERLEUKIN 2; PHYTOHEMAGGLUTININ; PHYTOHEMAGGLUTININ A; UNCLASSIFIED DRUG;

ACTIVATION INDUCED CELL DEATH; ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEPATITIS G; HEPATITIS G VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COINFECTION; FLAVIVIRIDAE INFECTIONS; FLOW CYTOMETRY; GB VIRUS C; HEPATITIS, VIRAL, HUMAN; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; PHYTOHEMAGGLUTININS; SIGNAL TRANSDUCTION; VIRAL LOAD; VIREMIA; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84865438261     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2309     Document Type: Article

References (40)

1. Stapleton JT. GB virus type C/hepatitis G virus. Semin Liver Dis 2003; 23:137-148. (Pubitemid 36666683)
2. Mohr EL, Stapleton JT. GB virus type C interactions with HIV: the role of envelope glycoproteins. J Viral Hepat 2009; 16:757-768.
3. Heringlake S, Ockenga J, Tillmann HL, et al. GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? J Infect Dis 1998; 177:1723-1726. (Pubitemid 28243603)
4. Toyoda H, Fukuda Y, Hayakawa T, Takamatsu J, Saito H. Effect of GB virus C/hepatitis G virus coinfection on the course of HIV infection in hemophilia patients in Japan. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:209-213.
5. Lefrère JJ, Ferec C, Roudot-Thoraval F, et al. GBV-C/hepatitis G virus (HGV) RNA load in immunodeficient individuals and in immunocompetent individuals. J Med Virol 1999; 59:32-37. (Pubitemid 29362162)
6. Yeo AE, Matsumoto A, Hisada M, Shih JW, Alter HJ, Goedert JJ. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Ann Intern Med 2000; 132:959-963. (Pubitemid 30397596)
7. Tillmann HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001; 345:715-724.
8. Xiang J, Wunschmann S, Diekema DJ, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001; 345:707-714.
9. Nunnari G, Nigro L, Palermo F, et al. Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile. Ann Intern Med 2003; 139:26-30.
10. Williams CF, Klinzman D, Yamashita TE, et al. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med 2004; 350:981-990. (Pubitemid 38269275)
11. Badley AD, Parato K, Cameron DW, et al. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ 1999; 6:420-432. (Pubitemid 29245956)
12. + T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol 2003; 84:1649-1661.
13. + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543.
14. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006; 12:289-295. (Pubitemid 43355074)
15. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9:235-245.
16. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-870. (Pubitemid 29159331)
17. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-1888. (Pubitemid 37070273)
18. + T cell count, and HIV plasma viral copy number. AIDS Res Hum Retroviruses 1999; 15:1509-1518.
19. Geeraert L, Kraus G, Pomerantz RJ. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 2008; 59:487-501. (Pubitemid 351287951)
20. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727-728. (Pubitemid 36749221)
21. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282:1627-1632. (Pubitemid 29513968)
22. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879-3884. (Pubitemid 351723493)
23. Rong L, Perelson AS. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLOS Comput Biol 2009; 5:e1000533.
24. Günthard HF, Wong JK, Spina CA, et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000; 181:522-531. (Pubitemid 30131819)
25. Tobin NH, Learn GH, Holte SE, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 2005; 79:9625-9634. (Pubitemid 41022306)
26. Wolschendorf F, Duverger A, Jones J, et al. Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction. J Virol 2010; 84:8712-8720.
27. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990; 9:1551-1560.
28. Copeland KF. Modulation of HIV-1 transcription by cytokines and chemokines. Mini Rev Med Chem 2005; 5:1093-1101. (Pubitemid 41723566)
29. Maidana-Giret MT, Silva TM, Sauer MM, et al. GB virus type C infection modulates T-cell activation independently of HIV-1 viral load. AIDS 2009; 23:2277-2287.
30. Stapleton JT, Chaloner K, Zhang J, et al. GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS 2009; 23:605-610.
31. Rodriguez B, Woolley I, Lederman MM, Zdunek D, Hess G, Valdez H. Effect of GB virus C coinfection on response to antiretroviral treatment in human immunodeficiency virus-infected patients. J Infect Dis 2003; 187:504-507. (Pubitemid 36184593)
32. Souza IE, Zhang W, Diaz RS, Chaloner K, Klinzman D, Stapleton JT. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians. HIV Med 2006; 7:25-31.
33. Antonucci G, Girardi E, Cozzi-Lepri A, et al. Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals. Antivir Ther 2005; 10:109-117. (Pubitemid 40767636)
34. George SL, Xiang J, Stapleton JT. Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures. Virology 2003; 316:191-201. (Pubitemid 37468523)
35. Xiang J, Klinzman D, McLinden J, et al. Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. J Virol 1998; 72:2738-2744. (Pubitemid 28175509)
36. Xiang J, George SL, Wunschmann S, Chang Q, Klinzman D, Stapleton JT. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 2004; 363:2040-2046. (Pubitemid 38781104)
37. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 2009; 7:798-812.
38. Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115:128-137. (Pubitemid 40385513)
39. George SL, Varmaz D, Stapleton JT. GB virus C replicates in primary T and B lymphocytes. J Infect Dis 2006; 193:451-454. (Pubitemid 43122346)
40. Moenkemeyer M, Schmidt RE, Wedemeyer H, Tillmann HL, Heiken H. GBV-C coinfection is negatively correlated to Fas expression and Fas-mediated apoptosis in HIV-1 infected patients. J Med Virol 2008; 80:1933-1940.